Journal: Neurological research

Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

doi: 10.1080/01616412.2021.1963620

Figure Lengend Snippet: Figure 1. The expression of IGFBP6 according to WHO grades, IDH status and 1p/19q status in CGGA and TCGA datasets. (a-c) IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in TCGA dataset (d-f). IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in CGGA dataset. Photographs of immuno histochemical staining of IGFBP6 in different grades of gliomas. Positive cells are stained brown. (g) Diffuse astrocytoma (WHO grade II). (h) Anaplastic astrocytoma (WHO grade III). (i) Glioblastoma multiforme (WHO grade IV). Magnification, x200. *, **, *** and **** indicate P < 0.05, P < 0.01, P < 0.001 and P < 0.0001, respectively.

Article Snippet: IGFBP6 Monoclonal Antibody (67,567-1-Ig, dilution: 1:200, Proteintech) was used to detect IGFBP6 protein expression.

Techniques: Expressing, Staining

Journal: Neurological research

Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

doi: 10.1080/01616412.2021.1963620

Figure Lengend Snippet: Figure 2. The difference of IGFBP6 in four TCGA molecular markers. (a, c) The expression of IGFBP6 was significantly upregulated in mesenchymal subtype in TCGA and CGGA datasets. (b, d) The ROC curves indicated that IGFBP6 expression exhibited highly sensitivity and specificity to predict mesenchymal subtype in TCGA and CGGA datasets. Area under curve (AUC) was 0.831 and 0.858, respectively. (e) Photographs of immunohistochemical staining of IGFBP6 in gliomas with different molecular subtypes. Positive cells are stained brown. Magnification, x200.

Article Snippet: IGFBP6 Monoclonal Antibody (67,567-1-Ig, dilution: 1:200, Proteintech) was used to detect IGFBP6 protein expression.

Techniques: Expressing, Immunohistochemical staining, Staining

Journal: Neurological research

Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

doi: 10.1080/01616412.2021.1963620

Figure Lengend Snippet: Figure 3. The gene ontology analysis of IGFBP6. (a, b) Heatmaps show the IGFBP6-related genes in CGGA and TCGA datasets. (c) The IGFBP6 expression was positively related with immune responses, immune cell migration, regulation of JAK-STAT pathway and so on. (d) The IGFBP6 expression was negatively related with the normal physiological functions of neurons and cells.

Article Snippet: IGFBP6 Monoclonal Antibody (67,567-1-Ig, dilution: 1:200, Proteintech) was used to detect IGFBP6 protein expression.

Techniques: Expressing, Migration

Journal: Neurological research

Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

doi: 10.1080/01616412.2021.1963620

Figure Lengend Snippet: Figure 4. IGFBP6 related checkpoints and inflammation activities in CGGA and TCGA cohorts. (a, b) IGFBP6 expression was positively correlated with PDCD1, PDCD1L2, HAVCR2 and CD274 expression. (c, d) The relationship between IGFBP6 expression and seven inflammation activities. In pie charts, positive correlations are displayed in green and negative correlations in red. Color intensity and the size of the circle are proportional to the correlation coefficients.

Article Snippet: IGFBP6 Monoclonal Antibody (67,567-1-Ig, dilution: 1:200, Proteintech) was used to detect IGFBP6 protein expression.

Techniques: Expressing

Journal: Neurological research

Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

doi: 10.1080/01616412.2021.1963620

Figure Lengend Snippet: Figure 5. IGFBP6 was a prognostic factor in glioma patients. (a-f) Kaplan–Meier survival analysis showed that high expression of IGFBP6 indicated a significantly worse OS in all grade glioma patients (p < 0.0001), GBM patients (p = 0.029), IDH mutant patients (p = 0.01) and IDH wild type (p = 0.015) patients in CGGA dataset. The lower level of IGFBP6 significantly increased glioma sensitivity to radiotherapy (p = 0.002) or chemotherapy (p = 0.034) in CGGA dataset. (g-j) Kaplan–Meier survival analysis showed that high expression of IGFBP6 indicated a significantly worse OS in all grade glioma patients (p < 0.0001), GBM patients (p = 0.0061), IDH mutant patients (p = 0.0283) and IDH wild type (p = 0.0037) patients in TCGA dataset.

Article Snippet: IGFBP6 Monoclonal Antibody (67,567-1-Ig, dilution: 1:200, Proteintech) was used to detect IGFBP6 protein expression.

Techniques: Expressing, Mutagenesis

Journal: British Journal of Cancer

Article Title: Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer

doi: 10.1038/sj.bjc.6602520

Figure Lengend Snippet: Insulin-like growth factor binding protein-6 (IGFBP-6) gene expression levels in PC-3 cells. Transcript levels were measured by quantitative real-time PCR after treatment with various concentrations of DES. 18s ribosomal RNA transcript levels were used for the internal control, and gene expression levels were expressed as fold changes relative to those of the controls. IGFBP-6 gene expression was significantly increased after DES treatment in a dose-dependent manner in PC-3 cells. The values are expressed as means+s.d. ( n =3), and the P -values were <0.05 ( * ) and <0.01 (†).

Article Snippet: DES (Sigma) was dissolved in DMSO, and recombinant insulin-like growth factor binding protein 6 (IGFBP-6) (Genzyme-techne, Minnesota, USA) was resuspended with PBS and stored at −70°C.

Techniques: Binding Assay, Expressing, Real-time Polymerase Chain Reaction

Journal: British Journal of Cancer

Article Title: Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer

doi: 10.1038/sj.bjc.6602520

Figure Lengend Snippet: Insulin-like growth factor binding protein-6 (IGFBP-6) protein levels in PC-3 cells. Protein levels were measured by Western blot analysis after treatment with various concentrations of DES. Proteins levels were expressed as fold changes. IGFBP-6 protein expression was significantly increased after DES treatment in a dose-dependent manner in PC-3 cells. The values were expressed as means+s.d. ( n =3), and the P -values were <0.05 ( * ) and <0.01 (†).

Article Snippet: DES (Sigma) was dissolved in DMSO, and recombinant insulin-like growth factor binding protein 6 (IGFBP-6) (Genzyme-techne, Minnesota, USA) was resuspended with PBS and stored at −70°C.

Techniques: Binding Assay, Western Blot, Expressing

Journal: British Journal of Cancer

Article Title: Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer

doi: 10.1038/sj.bjc.6602520

Figure Lengend Snippet: Inhibition of proliferation of human prostate cancer PC-3 cells by recombinant IGFBP-6. Cells were incubated for 24 h, and thereafter CM was aspirated away and the cells were incubated with CM containing various concentrations of IGFBP-6. After 48 h, the viable cell number was measured by MTT assay. The optical density (OD) of the cell lysates is expressed as the fold change. Recombinant IGFBP-6 inhibited the proliferation of PC-3 cells in a dose-dependent manner. The values are expressed as means+s.d. ( n =3), and the P -values were <0.05 ( * ).

Article Snippet: DES (Sigma) was dissolved in DMSO, and recombinant insulin-like growth factor binding protein 6 (IGFBP-6) (Genzyme-techne, Minnesota, USA) was resuspended with PBS and stored at −70°C.

Techniques: Inhibition, Recombinant, Incubation, MTT Assay

Journal: British Journal of Cancer

Article Title: Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer

doi: 10.1038/sj.bjc.6602520

Figure Lengend Snippet: Effects of IGFBP-6 and anti-IGFBP-6 antibody on PC-3 cell proliferation. Cells were incubated for 24 h, and thereafter CM was aspirated away. After 48 h of incubation of PC-3 cells with 800 ng ml −1 recombinant IGFBP-6 and various concentrations of anti-IGFBP-6 or normal goat IgG, the viable cell number was measured by MTT assay. The optical density (OD) of the cell lysates was expressed as the fold change. In total, 20–30 μ g ml −1 of anti-IGFBP-6 antibody significantly neutralised the inhibitory effects of cell proliferation. The values are expressed as means+s.d. ( n =3), and the P -values were <0.05 ( * ) and <0.1 (#).

Article Snippet: DES (Sigma) was dissolved in DMSO, and recombinant insulin-like growth factor binding protein 6 (IGFBP-6) (Genzyme-techne, Minnesota, USA) was resuspended with PBS and stored at −70°C.

Techniques: Incubation, Recombinant, MTT Assay

Journal: British Journal of Cancer

Article Title: Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer

doi: 10.1038/sj.bjc.6602520

Figure Lengend Snippet: Effect of neutralising anti-IGFBP-6 antibody on DES-treated PC-3 cells. Cells were incubated for 24 h, and thereafter CM was aspirated away. After 48 h incubation of PC-3 cells with 6.25 μ M DES and various concentrations of anti-IGFBP-6 antibody or normal goat IgG, the viable cell number was measured by MTT assay. The optical density (OD) of the cell lysates was expressed as the fold change. Cell proliferation was significantly upregulated by incubation with high-dose antibody (30 μ g ml −1 ). Anti-IGFBP-6 antibody inhibited DES-induced cell growth suppression. The values are expressed as means+s.d. ( n =3), and the P -values were <0.01 (†).

Article Snippet: DES (Sigma) was dissolved in DMSO, and recombinant insulin-like growth factor binding protein 6 (IGFBP-6) (Genzyme-techne, Minnesota, USA) was resuspended with PBS and stored at −70°C.

Techniques: Incubation, MTT Assay

Journal: British Journal of Cancer

Article Title: Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer

doi: 10.1038/sj.bjc.6602520

Figure Lengend Snippet: Immunohistochemical staining of IGFBP-6. IGFBP-6 was visible in the cytoplasm of cancer cells in the organ ( A ). For one patient, DESdP treatment increased the IGFBP-6 staining intensity in cancer cells ( B ). The immunostained section in ( B ) is from the same patient as that shown in ( A ). Cells that stained positively for IGFBP-6 are brown in colour.

Article Snippet: DES (Sigma) was dissolved in DMSO, and recombinant insulin-like growth factor binding protein 6 (IGFBP-6) (Genzyme-techne, Minnesota, USA) was resuspended with PBS and stored at −70°C.

Techniques: Immunohistochemical staining, Staining